A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Auron Therapeutics, Inc.
Incyte Corporation
Senti Biosciences
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Thomas Jefferson University
National Cancer Institute (NCI)
Novartis
Baylor College of Medicine
M.D. Anderson Cancer Center
Massachusetts General Hospital
University of Alabama at Birmingham
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
Johns Hopkins All Children's Hospital
AbbVie
Massachusetts General Hospital
AbbVie
Baylor College of Medicine
Foghorn Therapeutics Inc.
City of Hope Medical Center
Eli Lilly and Company
Orca Biosystems, Inc.
Dana-Farber Cancer Institute
Shenzhen TargetRx, Inc.
AbbVie
Northwestern University
Nkarta, Inc.
Precigen, Inc
University of Kansas Medical Center
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals